{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"41.4","value":"5200"}]}],"title":"Encorafenib: Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.2","value":"871"}]}],"title":"LHY746: Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"55.7","value":"3020"}]}],"title":"Encorafenib: Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"76.7","value":"1250"}]}],"title":"LHY746: Cycle 1 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Cmax was observed directly from data. LHY746 is a metabolite of Encorafenib.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"Phase 3: Arm A [EC]"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK parameter analysis set was analyzed. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. As pre-specified in the protocol of the study, 12 PK evaluable participants in Mainland China were randomized in Arm A, no additional participants were required from Arm B and participants did not receive encorafenib in Arm C. Hence, data is reported only for Arm A and not for Arms B and C.","reportingStatus":"POSTED","timeFrame":"Pre-dose (0 hr), 0.5, 1, 2, 3, 4, 5, 6, 8 and 24 hrs post-dose on Days 1 and 15 of Cycle 1","title":"Phase 3: Cmax of Encorafenib and Its Metabolite LHY746 in Mainland China Participants","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter"}